Immune Therapies in Practice in 2026: Cellular Therapies, ADCs, Bispecifics, and Beyond

Overview

Immune Therapies in Practice in 2026: Cellular Therapies, ADCs, Bispecifics and Beyond is a one-day educational conference jointly sponsored by the Fred Hutch Cancer Center and Physicians’ Education Resource (PER®).

This program will focus on the practical integration of next-generation immune-based therapies in select hematologic and solid tumors, examining how rapidly evolving treatment modalities are reshaping clinical care. Expert faculty will address the current and emerging roles of cellular therapies, antibody drug conjugates (ADCs), bispecific antibodies, and novel immune approaches, with an emphasis on real-world application. A dedicated focus will be placed on helping community oncology teams strengthen the infrastructure and workflows needed to operationalize bispecific antibodies, including patient identification, step up dosing logistics, standardized monitoring, toxicity triage, and escalation pathways.

Clinical discussions will center on the role of immune therapies in the management of:

• Breast Cancer
• Genitourinary Cancers
• Lymphoma 
• Melanoma
• Multiple Myeloma

The agenda will feature interactive discussion between expert faculty and community oncologists, fostering dialogue around treatment selection, sequencing, toxicity management, and evolving standards of care. This collaborative format is designed to support practical, evidence-based decision-making in everyday oncology practice.

Learning Objectives

Upon completion of this activity, learners will be better able to:

• Apply biomarkers and patient- and disease-specific factors to guide immunotherapy selection and sequencing
• Evaluate current and emerging immunotherapy strategies across solid and hematologic malignancies
• Examine multidisciplinary strategies to improve referral pathways and access to immunotherapy
• Implement best practices for monitoring and managing immunotherapy-related toxicities

Program Co-Chairs

Petros Grivas, MD, PhD, FASCO; Mazyar Shadman, MD, MPH

To view full profile, click on the Program Co-Chairs tab above.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Physicians' Education Resource®, LLC and Fred Hutch Cancer Center. Physicians' Education Resource®, LLC is accredited by the ACCME to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC, designates this live activity for a maximum of 7.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource^®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 7.0 Contact Hours.

Medical Oncologists (ABIM)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 7.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.